Journal
PROTEOMES
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/proteomes10020016
Keywords
ovarian cancer; signaling pathways; proteomic biomarkers; proteomic techniques; multiomics; peptidomics
Categories
Funding
- Department of Research and Innovation, Medway NHS Foundation Trust, Gillingham, Kent, UK
Ask authors/readers for more resources
Identifying ovarian cancer at early stages is challenging due to its heterogeneity. Next-generation sequencing and proteomics analysis can provide insights into the disease's molecular biology and adaptive responses to therapy, leading to improved treatment choices and outcomes.
The ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The patients present an advanced stage at diagnosis. This heterogeneous disease has distinguishable etiology and molecular biology. Next-generation sequencing changed clinical diagnostic testing, allowing assessment of multiple genes, simultaneously, in a faster and cheaper manner than sequential single gene analysis. Technologies of proteomics, such as mass spectrometry (MS) and protein array analysis, have advanced the dissection of the underlying molecular signaling events and the proteomic characterization of OC. Proteomics analysis of OC, as well as their adaptive responses to therapy, can uncover new therapeutic choices, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is an urgent need to better understand how the genomic and epigenomic heterogeneity intrinsic to OC is reflected at the protein level, and how this information could potentially lead to prolonged survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available